Idera Pharmaceuticals, a pharmaceutical solutions provider, completed the acquisition of Aceragen, a privately-held biotechnology company. Financial terms were not disclosed. “After a thorough evaluation of strategic alternatives, we and our Board of Directors believe this acquisition represents the highest potential value creation opportunity for Idera’s stockholders. We are excited by the potential for Aceragen’s rare disease portfolio to result in meaningful therapeutic options for patients, and I am looking forward to being part of this new stage of Idera’s journey,” Vincent Milano, Idera Chair of the Board.